Twin metabolic targeting of glutamine and glucose utilization pathways by way of inhibition of each glutaminase and progress aspect signaling pathways is hypothesized to synergize to suppress tumor cell proliferation in people with RCC (Supplementary Fig. S1). Cabozantinib, a VEGFR2/Satisfied/AXL in